18 - 09 - 2026

Tenthpin Opens Bengaluru Innovation Hub, To Hire India Workforce

Global life sciences consultancy Tenthpin has inaugurated a new office in Bengaluru and plans to more than double its workforce in India from approximately 175 employees to around 400 over the next 18 to 24 months, as it seeks to make the country a larger source of technology and domain-led innovation for its global operations.

The company said the Bengaluru facility will function as a global centre of excellence for life sciences innovation, bringing together artificial intelligence, cloud technologies and the Internet of Medical Things with expertise spanning pharmaceuticals, biotechnology, medical technology and advanced therapies.

The expansion represents a broader shift in Tenthpin’s India strategy, with the company seeking to position the country beyond its traditional role as a technology delivery and cost-efficiency destination. Its leadership said the focus in Bengaluru would instead be on specialised talent, life sciences expertise, product development and global innovation.

“India is now our largest entity, and a significant share of our innovation is coming from here,” said Juergen Bauer, co-founder and Executive Chairman of Tenthpin. He said India was not being treated as a low-cost delivery centre but as an integral part of Tenthpin’s global operating model.

Tenthpin currently employs around 650 people globally and serves approximately 70 to 72 customers. Its Indian teams support clients across Europe, the United States and other markets, working alongside teams located across multiple countries.

Bauer said Tenthpin’s presence in markets such as the UK, Switzerland, Germany and the US was largely driven by proximity to industry decision-makers, while India’s expansion was being supported by the country’s technology and life sciences talent pool.

“Cost may explain why many companies initially came to India, but it is not why we stay,” Bauer said, pointing instead to the scale of India’s talent ecosystem and its ability to support increasingly sophisticated technology and innovation programmes.

Bengaluru to drive India’s growth

Sachin Bhure, Partner and Managing Director of Tenthpin India, described the Bengaluru facility as “a new chapter” for the company. He said the city was selected for its concentration of life sciences companies, global capability centres, technology talent and research institutions.

Tenthpin expects Bengaluru to account for 60% to 70% of its future growth in India, with approximately 60% of the company’s recent Indian hiring already taking place in the city.

Bhure said the planned workforce expansion would focus on capabilities rather than simply increasing headcount. The company is looking for professionals with an understanding of internal business processes, technology and problem-solving, he said.

The Bengaluru hub will also expand Tenthpin’s technology portfolio beyond SAP. Its work will encompass manufacturing execution systems, customer relationship management, Salesforce and other technologies supporting end-to-end transformation across the life sciences value chain.

The centre is already involved in co-innovation initiatives with SAP, including work on clinical supply management and advanced therapies. Products and platforms being incubated in India include the T-Top platform, along with capabilities related to clinical supply and Advanced Therapy Orchestration.

AI adoption depends on data, governance

Artificial intelligence was a central theme at the inauguration, although Tenthpin executives cautioned that successful adoption in life sciences would depend on stronger data foundations, regulatory governance and human oversight.

Arvind Ganju, Product Management Leader for SAP Advanced Therapy Orchestration, said the industry was moving towards what SAP describes as the autonomous enterprise, with AI expected to influence activities ranging from drug discovery and clinical development to manufacturing, quality and commercial operations.

However, executives said many organisations still lack the data infrastructure required to realise the full potential of AI.

Clinical-trial information, for example, can remain fragmented or poorly digitised, while data from unsuccessful experiments and discontinued programmes may be difficult to access. Such gaps can limit the ability of AI systems to analyse historical evidence and generate useful insights.

Tenthpin said AI can accelerate areas such as candidate identification, drug-pipeline analysis, data consolidation and evaluation, but cannot independently remove biological, regulatory or operational bottlenecks.

Reliable data, integrated enterprise systems, mature processes and appropriately trained users remain essential to deploying AI effectively in highly regulated life sciences environments.

The company is currently discussing four or five AI-enabled products with clients. While specific details have not been disclosed, management indicated that some could move towards commercialisation around December, subject to product development and customer readiness.

Bauer said Tenthpin’s role was increasingly focused on closing the gap between what technology makes possible and what organisations are prepared to implement, with an emphasis on practical use cases and responsible deployment. Tenthpin said its product-development approach is driven by customer requirements rather than technology alone. The company works with clients to identify operational challenges and then develops solutions that can potentially be adapted for wider industry use.

Its customer base includes large pharmaceutical companies, mid-sized life sciences businesses, contract development and manufacturing organisations, biotechnology companies, medical technology firms and animal-health companies.

Its work spans research integration, clinical development, quality, manufacturing, supply chains and patient-centric operating models. The consultancy has collaborated with companies including Roche, Bayer and GSK, developing solutions around specific business requirements.

Tenthpin also works with 22 service providers and technology partners to supplement its capabilities.

Executives said the increasing complexity of advanced therapies and personalised medicine, combined with changing relationships among patients, healthcare providers and manufacturers, is creating demand for new technology-enabled operating models.

Bengaluru is expected to become a major development base for these capabilities as Tenthpin expands its Indian operations. As the company scales, Tenthpin executives identified talent availability as one of its most significant constraints and outlined plans to strengthen internal training and university partnerships.

Michael Schmidt, co-founder and Member of the Executive Board of Tenthpin, highlighted the company’s Tech University programme, established approximately six or seven years ago. The programme brings employees from India, the United States and Europe together for intensive training, team-building and knowledge-sharing.

While Tenthpin supports flexible and remote working, Schmidt said physical interaction remains important for building a knowledge-based organisation and strengthening collaboration across international teams.

The company also operates structured programmes for young professionals, combining internships with nine to 12 months of training to prepare participants for careers in life sciences consulting. Tenthpin has worked with universities in Pune and is exploring additional collaborations in Bengaluru, including with Christ University.

Gowri Allada, Director India of Tenthpin, said the new facility represented more than an expansion of physical infrastructure. He described it as a shared “home office” and a symbol of the company’s commitment to collaboration, innovation and future growth.

The Bengaluru inauguration brought together Tenthpin executives, SAP representatives, employees, industry partners and members of the media.

With its planned expansion from about 175 employees to 400, Tenthpin is positioning Bengaluru as a strategic component of its global business rather than simply an offshore delivery location. The company’s stated ambition is to use India’s combination of technology expertise and life sciences talent to develop solutions for a global industry undergoing rapid transformation through AI, advanced therapies and increasingly digital operating models.

If you spotted a mistake or have feedback on this story, write to us at editor@newsassociate.com. Email us your press releases on the same ID.